Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen- independent prostate cancer

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1307-1318

  Graham, Martin C ^a,c   Scher, Howard I ^a,b   Liu, Gen Bao ^a,d   Yeh, Samuel D J ^a   Curley, Tracy ^a,b   Daghighian, Farhad ^a   Goldsmith, Stanley J ^a,b   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c Memorial Hospital   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ETIDRONIC ACID RE 186; PROSTATE SPECIFIC ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

ANDROGENS; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETIDRONIC ACID; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; ORGANOMETALLIC COMPOUNDS; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; WHOLE-BODY COUNTING;

EID: 0033048808     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Scher, H. I., and Chung, L. W. K. Bone metastases: biology and therapy. Semin. Oncol., 21: 630-656, 1994.
2. Scher, H. I., Mazumdar, M., and Kelly, W. K. Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst., 88: 1623-1634, 1996.
3. Scher, H. I. Cytotoxic chemotherapy for advanced prostate cancer: does it work, and if so, how do we prove it? ASCO Educational Book, 356-367, Alexandria, VA, 1998.
4. Tannock, I. F., Osoba, D., Stockier, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M. L., and Murphy, K. C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 14: 1756-1764, 1996.
5. Small, E. J., Marshall, M. E., Reyno, L., Meyers, F., Natale, R., Meyer, M., Lenehan, P., Chen, L., and Eisenberger, M. Superiority of suramin + hydrocortisone (S + H) over placebo + hydrocortisone (P+H): results of a multicenter double-blind phase III study in patients with hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol., 19: 1998.
6. Claringbold, P. G., and Turner, J. H. A phase II study of the treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153-ethylenediaminetetramethylene phosphonate (Sm-153-EDTMP). Proc. Am. Soc. Clin. Oncol., 10: 108, 1991.
7. Lattimer, J. C., Corwin, L. A., Stapleton, J., Volkert, W. A., Ehrhardt, G. J., Ketring, A. R., Hewett, J. E., Simon, J., and Goeckeler, W. F. Clinical and pathological effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J. Nucl. Med., 31: 586-593, 1990.
8. Turner, J. H., Claringbold, P. G., Hetherington, E. L., Sorby, P., and Martindale, A. A. A phase I study of samarium-153 ethylenediaminetetramethylene phosphate therapy for disseminated skeletal metastases. J. Clin .Oncol., 7: 1926-1931, 1989.
9. Collins, C., Eary, J., Nemiroff, C., Carichner, S., Appelbaum, F. R., Livingstone, R. B., and Gordon, E. E. Phase I trial of samarium (SM) 153-EDTMP in hormone refractory D2 prostate carcinoma. Proc. Am. Soc. Clin. Oncol., 9: 134, 1990.
10. Farhangi, M., Holmes, R. A., Volkert, W. A., Logan, K. W., and Singh, A. 153-Sm-EDTMP, a radiotherapeutic agent for palliative treatment of metastatic bone cancer pain. J. Nucl. Med., 33: 1451-1458, 1992.
11. Logothetis, C. J., Dexeus, F., and Chong, C. D. K. Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer. In: D. E. Johnson, C. J. Logothetis, and A. C. von Eschenbach (eds.), Systemic Therapy for Genitourinary Cancers, pp. 234-238. Chicago: Year Book Medical Publishers, 1992.
12. Maxon, H. R., Deutsch, E. A., Thomas, S. R., Libson, K., Lukes, S. J., Williams, C. C., and Ali, S. Re-186-HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology, 166: 501-507, 1988.
13. Maxon, H. R., Schroder, L. E., Thomas, S. R., Hertzberg, V. S., Deutsch, E. A., Scher, H. I., Samaratunga, R. C., Libson, K. F., Williams, C. C., Moulton, J. S., and Schneider, H. J. 186-Re(Sn)-HEDP for the treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone resistant prostatic cancer. Radiology, 176: 155-159, 1990.
14. Maxon, H. R., Thomas, S. R., Hertzberg, V. S., Schroder, L. E., Englaro, E. E., Samaratunga, R. Scher, H. I., Moulton, J. S., Deutsch, E. A., Deutsch, K. F., Schneider, J. H., Williams C. C., and Ehrhardt, G. J. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin. Nuclear Med., 22: 33-40, 1992.
15. Green, S., and Weiss, G. R., Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Inv. New Drugs, 10: 239-253, 1992.
16. Browne, E., Firestone, R. B., and Shirley, V. S. Table of Radioactive Isotopes. New York, John Wiley & Sons, 1986.
17. Thomas, S. R., Maxon, H. R., and Kereiakes, J. G. In vivo quantitation of lesion radioactivity using external counting methods. Med. Phys., 3: 253-255, 1976.
18. Thomas, S. R., Maxon, H. R., Kereiakes, J. G., and Saenger, E. L. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology, 122: 731-737, 1977.
19. Fleming, J. S. A technique for the absolute measurement of activity using a gamma cancer and computer. Phys. Med. Biol., 24: 176-180, 1979.
20. Pentlow, K. S., Liu, G., Graham, M. C., Yeh, S. D-J., Finn, R., Scher, H. I., and Larson, S. M. Quantitative imaging of rhenium-186. Med. Phys., 19: 844-845, 1992.
21. Snyder, W. S., Ford, M. R., Warner, C. G., and Watson, S. B. "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. Medical Internal Radiation Dosimetry Pamphlet, Ed. 11. New York: Society of Nuclear Medicine, 1975.
22. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. Ann. Int. Comm. Radiol. Prot., 30: 1979.
23. Weber, D. A., Mekler, P. T., Watson, E. E., Coffey, J. L., Thomas, S. R., and Londou, J. MIRD Dose estimate report no. 13. Radiation absorbed dose from Tc-99m-labeled bone imaging agents. J. Nucl. Med., 30: 1117-1122, 1989.
24. Bayouth, J. E., and Macey, D. J. Dosimetry considerations of bone-seeking radionuclides for marrow ablation. Med. Phys., 20: 1089-1096, 1993.
25. Scher, H., Curley, T., Graham, M. C., Yeh, S., Liebertz, C., Kelly, W., and Larson, S. Phase I trial of escalated dose of rhenium-186-hydroxyethylidene diphosphonate [RE-186-HEDP] in patients with metastatic prostate cancer to bone. Proc. Am. Soc. Clin. Oncol., 13: abstract 242, 1994.
26. Maxon, H. R., III, Schroder, L. E., Hertzberg, V. S., Thomas, S. R., Ehglaro, E. E., Samaratunga, R., Smith, H., Moulton, J. S., Williams, C. C., Ehrhardt, G. J., and Schneider, H. J. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind cross-over comparison with placebo. J. Nucl. Med., 32: 1877-1881, 1991.
27. de Klerk, J. M. H., van het Schip, A. D., Zonnenberg, B. A., Dijk, A. V., Stokkel, M. P. M., Han, S. H., Blijham, G. H., and van Rijk, P. P. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J. Nucl. Med., 35: 1423-1428, 1994.
28. Risau, W. Embryonic angiogenesis factors. Pharmacol. Ther., 51: 371-376, 1991.
29. Poulter, C. A., Cosmatos, D., Rubin, P., Urtasun, R., Cooper, J. S., Kuske, R. R., Hornback, N., Coughlin, C., Weigensberg, I., and Rotman, M. A report of RTOG 8206: a phase-III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int. J. Radiat. Oncol. Biol. Phys., 23: 207-214, 1992.
30. Elgazzar, A. H., and Maxon, H. R., III. Radioisotope therapy for cancer related bone pain. Imag. Ins., 2: 1-6, 1993.
31. Lewington, V. J. Targeted radionuclide therapy for bone metastases. Eur. J. Nucl. Med., 20: 66-74, 1993.
32. Dowd, M. T., Chen C-T., Wendel, M. J., Faulhaber, P. J., and Cooper, M. D. Radiation dose to the bladder wall from 2-[18F] fluro-2-deoxy-D-glucose in adult humans. J. Nucl. Med., 32: 707-712, 1991.
33. Graham, M. C., Ballon, D., Koutcher, J. A., Schneider, E., and Larson, S. M. A new method of marrow dosimetry integrating cellularity volume, and isotope activity measurements using chemical shift NMR images registered with SPECT and for PET: initial phantom results, Med. Phys., 21: 910, abstract M9, 1994.
34. Eary, J. F., Collins, C., Stabin, M., Vernon, C., Petersdorf, S., Baker, M., Hartnett, S., Ferency, S., Addison, S. J., Appelbaum, F., and Gordan, E. E. Samarium-153-EDTMP biodistribution and dosimetry estimation. J. Nucl. Med., 34: 1031-1036, 1993.
35. Graham, C. W., Lynch, J. H., and Djakiew, D. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J. Urol., 147: 1444-1447, 1992.
36. Scher, H. I., and Yagoda, A. Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors. Am. J. Med., 82: 6-28, 1987